Reduced Cerebrospinal Fluid Biomarkers (Neurofilament Light Chain, B Cells, T Cells) and Improved Clinical/Imaging Assessments of Disease Activity Are Sustained After 5 Years of Ocrelizumab Treatment: Long-term Extension Results from OBOE (P6-1.002)
To report OBOE (NCT02688985) long-term extension (LTE) findings post ocrelizumab treatment in people with relapsing multiple sclerosis (pwRMS).
Authors
- Jenny Jiang (ORCID: https://orcid.org/0000-0003-0341-1385)
- H.‐Christian von Büdingen (ORCID: https://orcid.org/0000-0003-0159-6662)
- Briana Cameron (ORCID: https://orcid.org/0000-0001-5940-8252)
- David Clayton (ORCID: https://orcid.org/0000-0002-3850-8200)
- Jeffrey Marc Gelfand (ORCID: https://orcid.org/0000-0002-5121-3319)
- Xiaoming Jia (ORCID: https://orcid.org/0000-0002-5104-5431)
- Ryan C. Winger (ORCID: https://orcid.org/0000-0001-9160-6646)
- Christopher Harp (ORCID: https://orcid.org/0000-0001-7000-8743)
- Amit Bar‐Or (ORCID: https://orcid.org/0000-0001-7179-0335)
- Ann Herman
- Anne H. Cross (ORCID: https://orcid.org/0000-0003-0829-7569)
- Yun‐An Shen
Institutions
- Roche (Switzerland) (CH)
- University of California, San Francisco (US)
- California University of Pennsylvania (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210699
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00